Processa pharmaceuticals announces first patient dosed in phase 2 clinical trial of ngc-cap in metastatic breast cancer

Hanover, md., oct. 02, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (processa or the company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a phase 2 clinical trial evaluating ngc-cap for the treatment of advanced or metastatic breast cancer.
PCSA Ratings Summary
PCSA Quant Ranking